CLINICAL PSYCHOPHARMACOLOGY COMPUTER LABORATORY

临床精神药理学计算机实验室

• 批准号: 2244329
• 负责人: JOHN E OVERALL
• 金额: $ 7.26万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-09-01 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2244329
• 关键词: clinical trials; computer simulation; health science research analysis /evaluation; human data; psychometrics; psychopharmacology; statistics /biometry; technology /technique development

This project is concerned with enhancing validity and power of neuropsychopharmacologic research and service delivery through refinements in design and analysis of controlled clinical trials, development and/or evaluation of clinical assessment and classification methodology, as well as the provision of statistical support for selected clinical investigators. Flexibility in focusing on key methodological issues as they arise has been a unique feature of this NIMH grant in the past. Evaluating neuropsychopharmacologic treatments in the broader service delivery context is a currently added emphasis that poses novel methodological problems and possibilities. Statistical issues to be examined include the best among imperfect ways of controlling for confounding factors in doctor's choice treatment settings and methodology for investigating differences in frequencies of occurrence of rare events which can only be studied in the broader service delivery context. Computer models, monte carlo simulation methods, and logical analysis will be used to examine key issues in the methodology for evaluating neuropsychopharmacologic treatments. The importance of an independent academic participation in issues that arise at the interface of industry and the FDA is stressed.

该项目涉及提高有效性和力量 神经心理药理学研究和服务通过改进 在对照临床试验，开发和/或的设计和分析中 临床评估和分类方法的评估 作为为选定临床提供统计支持的提供 调查人员。 专注于关键方法论问题的灵活性 过去，它们一直是这项NIMH赠款的独特功能。 在更广泛的服务中评估神经心理药物治疗 交付环境是当前构成新颖的重点 方法论问题和可能性。 统计问题是 检查包括在控制方式中最好的 医生选择治疗环境和方法中的混杂因素 用于研究罕见事件发生频率的差异 只能在更广泛的服务交付环境中进行研究。 计算机模型，蒙特卡洛模拟方法和逻辑分析将 用于检查评估方法中的关键问题 神经心理药物治疗。 独立的重要性 学术参与行业界面上出现的问题 FDA压力很大。